科研成果: 1. 科研项目 (1) 主持国家自然科学基金面上项目等国家级项目2项; (2) 主持省级杰出青年基金项目等省级或校级科研项目近10项。
2. 所获成果(包括科研成果奖、专利、专著等) (1) 省级自然科学二等奖 1项(参与); (2) 国家1类新药 临床批件 1项(参与); (3) 以第一发明人身份申请发明专利10余项,代表性授权专利如下所示: a. 一种乙烷-1,2-双(3-芳基丙烯酸酯)类化合物及其在药物制备中的应用,申请日:2022.08.09,授权日:2024.10.15; b. 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用,申请日:2017.10.23,授权日:2020.11.24; c. 一种化合物及其制备由Flt3/c-Met激酶高表达所引起疾病的药物的应用,申请日:2020.09.14,授权日:2021.10.29; d. 含三氮唑或喹啉酮结构的吡啶酰胺类化合物及其应用,申请日:2019 .11 .07,授权日:2023.02.09。
3. 发表论文(具有代表性的5篇) (1) Discovery of c-Kit as a New Therapeutic Target in LPS-induced Acute Lung Injury Through Novel Phenylamide Derivative D9 [J]. Journal of Medicinal Chemistry, 2025, Accept,https://doi.org/10.1021/acs.jmedchem.4c03229 (通讯作者,1区Top期刊); (2) Discovery of novel MyD88 inhibitor A5S to alleviate acute lung injury with favorable drug-like properties [J]. Journal of Medicinal Chemistry, 2024, 67, 22263−22281 (通讯作者,1区Top期刊);(3) Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury [J]. Journal of Medicinal Chemistry, 2024, 67, 10687−107093 (通讯作者,1区Top期刊); (4) Novel O-benzylcinnamic acid derivative L26 Treats Acute Lung Injury in Mice by MD-2 [J]. European Journal of Medicinal Chemistry, 2023, 252, 115289 (通讯作者,1区Top期刊); (5) Discovery of 4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide derivatives as novel anti-inflammatory agents for the treatment of acute lung injury and sepsis [J]. European Journal of Medicinal Chemistry, 2023, 249, 115144 (通讯作者,1区Top期刊). |